* KALA BIO Inc KALA.OQ KALA.O is expected to show no
change in
quarterly revenue when it reports results on August 2
(estimated) for the period ending June 30 2024
*
* LSEG's mean analyst estimate for KALA BIO Inc is for a
loss of
$4.40 per share.
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for KALA BIO
Inc is
$16.50, above its last closing price of $6.47.
This summary was machine generated July 31 at 15:13 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)